Child Mortality, Child Morbidity
Conditions
Brief summary
This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.
Interventions
BIOLOGICALMeasles vaccine
Sponsors
Bandim Health Project
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Months to 24 Months
Healthy volunteers
Yes
Inclusion criteria
* Children need to have received the third dose of inactivated vaccines (Penta, PCV13 and IPV) before measles vaccination.
Exclusion criteria
* Having severe malformations that impairs their health * Having received a second dose of measles vaccine * Severely ill (requiring hospitalization) upon clinical examination
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 30 months | Mortality registered monthly by Health and Demographic Surveillance System fieldworkers. Mortality will be combined with hospital admissions in the analysis to form the outcome severe morbidity. This will be examined overall and by sex |
| Hospital admissions | 30 months | Hospital admissions registered daily at the national hospital. Hospital admissions will be combined with mortality in the analysis to form the outcome severe morbidity. This will be examined overall and by sex |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospital admission by cause | 30 months | Causes of hospital admissions registered daily at the national hospital. These will be examined overall and by sex |
| Consultations | 30 months | Consultations registered daily at the local health centers and the national hospital. These will be examined overall and by sex |
Countries
Guinea-Bissau
Outcome results
None listed